07-05-2025
This Biotech Found Mid-Week Success Following Analyst Upgrade
A biotech company based out of Massachusetts found a tremendous amount of success on Wednesday after Leerink Partners upgraded the stock from market perform to outperform, raising their price target for the stock from $4 to $10.
Traders wasted no time buying up shares of Amylyx Pharmaceuticals Inc. (Nasdaq:AMLX), pushing the small cap to close up at $4.87/share (+4.73%) on the day. This doesn't come at too much of a surprise given the bullish price target versus yesterday's close at just $4.65.
This move was a strong continuation of the success this stock has had over the last month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on
About Media, Inc.:
Founded in 1999, is one of North America's leading platforms for micro-cap insights.
Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.
is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.
Contact:
Media, Inc.
